Peringatan Keamanan

Death has occurred within 17 minutes of ingestion.

Tetrodotoxin

DB05232

small molecule investigational

Deskripsi

An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction. Tetrodotoxin is being investigated by Wex Pharmaceuticals for the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.

Struktur Molekul 2D

Berat 319.268
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1593 Data
Buprenorphine Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Hydrocodone Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Magnesium sulfate The therapeutic efficacy of Tetrodotoxin can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Tetrodotoxin may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Mirtazapine Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Orphenadrine Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Pramipexole Tetrodotoxin may increase the sedative activities of Pramipexole.
Ropinirole Tetrodotoxin may increase the sedative activities of Ropinirole.
Rotigotine Tetrodotoxin may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Tetrodotoxin.
Sodium oxybate Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Thalidomide Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Hyaluronidase (ovine) Hyaluronidase (ovine) can cause an increase in the absorption of Tetrodotoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) can cause an increase in the absorption of Tetrodotoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase Hyaluronidase can cause an increase in the absorption of Tetrodotoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Tetrodotoxin.
Ethanol Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Fluvoxamine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Alaproclate.
Technetium Tc-99m tilmanocept Tetrodotoxin may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Tetrodotoxin.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Tetrodotoxin.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Tetrodotoxin.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Tetrodotoxin.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Tetrodotoxin.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Tetrodotoxin.
Cocaine The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Tetrodotoxin.
Quinidine The risk or severity of methemoglobinemia can be increased when Quinidine is combined with Tetrodotoxin.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Tetrodotoxin.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Tetrodotoxin.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Tetrodotoxin.
Pizotifen The risk or severity of CNS depression can be increased when Tetrodotoxin is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Tetrodotoxin is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Tetrodotoxin.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Tetrodotoxin.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Tetrodotoxin.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.
Lorazepam The risk or severity of methemoglobinemia can be increased when Lorazepam is combined with Tetrodotoxin.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Tetrodotoxin.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Tetrodotoxin.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Tetrodotoxin.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Tetrodotoxin.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Tetrodotoxin.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Tetrodotoxin.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Tetrodotoxin.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Tetrodotoxin.
Butalbital The risk or severity of methemoglobinemia can be increased when Butalbital is combined with Tetrodotoxin.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Tetrodotoxin.
Cabergoline The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Tetrodotoxin.
Phenytoin The risk or severity of methemoglobinemia can be increased when Phenytoin is combined with Tetrodotoxin.
Topiramate The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Tetrodotoxin.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Tetrodotoxin.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Tetrodotoxin.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Tetrodotoxin.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Tetrodotoxin.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Tetrodotoxin.
Pentobarbital The risk or severity of methemoglobinemia can be increased when Pentobarbital is combined with Tetrodotoxin.
Valproic acid The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Tetrodotoxin.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tetrodotoxin.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Tetrodotoxin.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Tetrodotoxin.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Tetrodotoxin.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Tetrodotoxin.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Tetrodotoxin.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Tetrodotoxin.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Tetrodotoxin.
Trimethadione The risk or severity of methemoglobinemia can be increased when Trimethadione is combined with Tetrodotoxin.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Tetrodotoxin.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Tetrodotoxin.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Tetrodotoxin.

Target Protein

Sodium channel protein type 5 subunit alpha SCN5A
Sodium channel protein type 1 subunit alpha SCN1A
Sodium channel protein type 2 subunit alpha SCN2A
Sodium channel protein type 3 subunit alpha SCN3A
Sodium channel protein type 8 subunit alpha SCN8A

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Tectin
  • Tetrodin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul